# GDF5

## Overview
Growth Differentiation Factor 5 (GDF5) is a gene that encodes a protein belonging to the bone morphogenetic protein (BMP) family, which is part of the larger transforming growth factor-beta (TGF-β) superfamily. The GDF5 protein plays a pivotal role in skeletal development, particularly in the formation and maintenance of synovial joints, cartilage, and bone. It functions as a signaling molecule in the extracellular matrix, influencing cellular processes such as proliferation, differentiation, and apoptosis through its interaction with specific BMP receptors (Ratnayake2014Human; Reynard2011Expression). GDF5 is crucial for chondrogenesis and chondrocyte proliferation, and its activity is modulated by post-translational modifications and interactions with other proteins, such as the BMP antagonist Noggin (NOG) (Nickel2005A; Seemann2009Mutations). Mutations in the GDF5 gene are linked to various skeletal disorders, including brachydactyly and chondrodysplasias, underscoring its importance in normal bone and joint development (Byrnes2010Mutations; Genovesi2021GDF5).

## Structure
The molecular structure of Growth Differentiation Factor 5 (GDF5) is characterized by its membership in the TGF-β superfamily, sharing structural similarities with other bone morphogenetic proteins (BMPs) such as BMP-2 and BMP-7. GDF5 forms a homodimer through a disulfide bond at Cys84, with the dimer exhibiting a butterfly-shaped architecture stabilized by a cystine knot at its core (Nickel2005A; Kotzsch2009Crystal). Each monomer of GDF5 contains two beta-sheets forming the 'fingers', a four-turn alpha-helix as the 'wrist', and a cystine knot as the 'palm' (Nickel2005A).

The primary structure of GDF5 includes a signal peptide, a propeptide region, and a mature peptide. The secondary structure is defined by the beta-sheets and alpha-helix, contributing to the protein's overall fold. The tertiary structure involves the arrangement of these elements into a left-hand fold, with specific hydrogen bonds stabilizing the structure starting from residue Ala17 (Nickel2005A).

Post-translational modifications such as glycosylation and phosphorylation are common in GDF5, contributing to its functional regulation. The protein's quaternary structure is a homodimer, similar in architecture to other BMPs, but with unique structural deviations that influence receptor binding specificity (Nickel2005A; Kotzsch2009Crystal).

## Function
GDF5, a member of the TGF-beta superfamily, plays a crucial role in the development, maintenance, and repair of synovial joints. It is involved in chondrogenesis and chondrocyte proliferation, which are essential for normal skeletal, bone, and joint development (Reynard2011Expression). GDF5 is expressed in a pattern that precedes the development of the joint cavity and is involved in the formation of various joint structures, including articular cartilage, joint capsules, and ligaments (Chen2016Heads). 

The protein is active in the extracellular matrix, where it influences cellular processes such as proliferation, differentiation, and apoptosis. GDF5 signaling involves BMP receptors, including BMPR1A, BMPR1B, and BMPR2, leading to the phosphorylation of Smad1/5/8 signaling molecules. These molecules form a complex with Smad 1/4 and translocate into the nucleus to regulate the transcription of target genes like COL2A1 and ACAN, which encode type II collagen and aggrecan, the principal structural proteins of cartilage (Ratnayake2014Human).

GDF5 is also involved in the growth and homeostasis of intervertebral discs, stimulating anabolic activities in nucleus pulposus cells by increasing the synthesis of type II collagen and aggrecan (Colombier2015TGFβ1). Its expression is modulated by DNA methylation, affecting transcriptional activity and influencing osteoarthritis susceptibility (Reynard2011Expression).

## Clinical Significance
Mutations in the GDF5 gene are associated with a variety of skeletal disorders. These include brachydactyly types A1, A2, and C, which are characterized by shortened bones in the hands and feet (Byrnes2010Mutations; Genovesi2021GDF5). Brachydactyly type A2 (BDA2) is linked to the L441P mutation, which results in reduced binding affinity to the BMPR1B receptor, leading to a loss of function (Seemann2005Activating). Brachydactyly type C (BDC) can result from heterozygous frameshift mutations (Genovesi2021GDF5).

GDF5 mutations also cause more severe conditions such as Grebe type chondrodysplasia and Hunter-Thompson type acromesomelic chondrodysplasia, which are associated with homozygous frameshift mutations (Genovesi2021GDF5). Multiple synostoses syndrome 2 (SYNS2) and proximal symphalangism are linked to mutations that alter receptor interactions, such as the R438L mutation, which increases binding to BMPR1A (Seemann2005Activating; Degenkolbe2013A).

Alterations in GDF5 expression levels can also affect osteoarthritis susceptibility, as indicated by a single nucleotide polymorphism in the gene's 5' untranslated region (Genovesi2021GDF5). These mutations and alterations highlight the critical role of GDF5 in bone and joint development.

## Interactions
GDF5 interacts with several proteins, primarily through its role in the bone morphogenetic protein (BMP) signaling pathway. It binds to BMP receptors, specifically showing a preference for BMPR-IB over BMPR-IA, due to the presence of the Arg57 residue, which is crucial for its receptor specificity (Nickel2005A). Mutations at this site, such as R57A, alter its receptor binding properties, allowing it to bind both BMPR-IA and BMPR-IB with similar affinity (Nickel2005A; Klammert2015GDF-5).

GDF5 also interacts with type II receptors, including ActR-II, ActR-IIB, and BMPR-II, which are involved in its signaling processes (Klammert2015GDF-5). The protein can form functional signaling complexes with these receptors, influencing biological activities such as the induction of alkaline phosphatase expression in certain cell types (Nickel2005A).

GDF5's interaction with the BMP antagonist Noggin (NOG) is also significant. Mutations like N445T in GDF5 can alter its interaction with NOG, affecting the regulation of BMP signaling (Seemann2009Mutations). These interactions are crucial for understanding GDF5's role in bone and joint development.


## References


[1. (Seemann2009Mutations) Petra Seemann, Anja Brehm, Jana König, Carsten Reissner, Sigmar Stricker, Pia Kuss, Julia Haupt, Stephanie Renninger, Joachim Nickel, Walter Sebald, Jay C. Groppe, Frank Plöger, Jens Pohl, Mareen Schmidt-von Kegler, Maria Walther, Ingmar Gassner, Cristina Rusu, Andreas R. Janecke, Katarina Dathe, and Stefan Mundlos. Mutations in gdf5 reveal a key residue mediating bmp inhibition by noggin. PLoS Genetics, 5(11):e1000747, November 2009. URL: http://dx.doi.org/10.1371/journal.pgen.1000747, doi:10.1371/journal.pgen.1000747. This article has 80 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1000747)

[2. (Ratnayake2014Human) Madhushika Ratnayake, Frank Plöger, Mauro Santibanez-Koref, and John Loughlin. Human chondrocytes respond discordantly to the protein encoded by the osteoarthritis susceptibility gene gdf5. PLoS ONE, 9(1):e86590, January 2014. URL: http://dx.doi.org/10.1371/journal.pone.0086590, doi:10.1371/journal.pone.0086590. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0086590)

[3. (Reynard2011Expression) Louise N. Reynard, Catherine Bui, Elizabeth G. Canty-Laird, David A. Young, and John Loughlin. Expression of the osteoarthritis-associated gene gdf5 is modulated epigenetically by dna methylation. Human Molecular Genetics, 20(17):3450–3460, June 2011. URL: http://dx.doi.org/10.1093/hmg/ddr253, doi:10.1093/hmg/ddr253. This article has 96 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddr253)

[4. (Colombier2015TGFβ1) Pauline Colombier, Johann Clouet, Cécile Boyer, Maëva Ruel, Gaëlle Bonin, Julie Lesoeur, Anne Moreau, Borhane-Hakim Fellah, Pierre Weiss, Laurent Lescaudron, Anne Camus, and Jérôme Guicheux. Tgf-β1 and gdf5 act synergistically to drive the differentiation of human adipose stromal cells toward nucleus pulposus-like cells. Stem Cells, 34(3):653–667, December 2015. URL: http://dx.doi.org/10.1002/stem.2249, doi:10.1002/stem.2249. This article has 61 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/stem.2249)

[5. (Seemann2005Activating) P. Seemann. Activating and deactivating mutations in the receptor interaction site of gdf5 cause symphalangism or brachydactyly type a2. Journal of Clinical Investigation, 115(9):2373–2381, August 2005. URL: http://dx.doi.org/10.1172/jci25118, doi:10.1172/jci25118. This article has 181 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci25118)

[6. (Degenkolbe2013A) Elisa Degenkolbe, Jana König, Julia Zimmer, Maria Walther, Carsten Reißner, Joachim Nickel, Frank Plöger, Jelena Raspopovic, James Sharpe, Katarina Dathe, Jacqueline T. Hecht, Stefan Mundlos, Sandra C. Doelken, and Petra Seemann. A gdf5 point mutation strikes twice - causing bda1 and syns2. PLoS Genetics, 9(10):e1003846, October 2013. URL: http://dx.doi.org/10.1371/journal.pgen.1003846, doi:10.1371/journal.pgen.1003846. This article has 32 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1003846)

[7. (Klammert2015GDF-5) Uwe Klammert, Thomas D. Mueller, Tina V. Hellmann, Kristian K. Wuerzler, Alexander Kotzsch, Anna Schliermann, Werner Schmitz, Alexander C. Kuebler, Walter Sebald, and Joachim Nickel. Gdf-5 can act as a context-dependent bmp-2 antagonist. BMC Biology, September 2015. URL: http://dx.doi.org/10.1186/s12915-015-0183-8, doi:10.1186/s12915-015-0183-8. This article has 36 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1186/s12915-015-0183-8)

[8. (Nickel2005A) Joachim Nickel, Alexander Kotzsch, Walter Sebald, and Thomas D. Mueller. A single residue of gdf-5 defines binding specificity to bmp receptor ib. Journal of Molecular Biology, 349(5):933–947, June 2005. URL: http://dx.doi.org/10.1016/j.jmb.2005.04.015, doi:10.1016/j.jmb.2005.04.015. This article has 120 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2005.04.015)

[9. (Byrnes2010Mutations) Ashley M. Byrnes, Lemuel Racacho, Sarah M. Nikkel, Fengxia Xiao, Heather MacDonald, T. Michael Underhill, and Dennis E. Bulman. Mutations in gdf5 presenting as semidominant brachydactyly a1. Human Mutation, 31(10):1155–1162, September 2010. URL: http://dx.doi.org/10.1002/humu.21338, doi:10.1002/humu.21338. This article has 19 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.21338)

[10. (Chen2016Heads) Hao Chen, Terence D. Capellini, Michael Schoor, Doug P. Mortlock, A. Hari Reddi, and David M. Kingsley. Heads, shoulders, elbows, knees, and toes: modular gdf5 enhancers control different joints in the vertebrate skeleton. PLOS Genetics, 12(11):e1006454, November 2016. URL: http://dx.doi.org/10.1371/journal.pgen.1006454, doi:10.1371/journal.pgen.1006454. This article has 63 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1006454)

[11. (Kotzsch2009Crystal) Alexander Kotzsch, Joachim Nickel, Axel Seher, Walter Sebald, and Thomas D Müller. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for gdf-5–type i receptor specificity. The EMBO Journal, 28(7):937–947, February 2009. URL: http://dx.doi.org/10.1038/emboj.2009.37, doi:10.1038/emboj.2009.37. This article has 54 citations.](https://doi.org/10.1038/emboj.2009.37)

[12. (Genovesi2021GDF5) Maria Luce Genovesi, Daniele Guadagnolo, Enrica Marchionni, Agnese Giovannetti, Alice Traversa, Noemi Panzironi, Silvia Bernardo, Pietro Palumbo, Francesco Petrizzelli, Massimo Carella, Tommaso Mazza, Antonio Pizzuti, and Viviana Caputo. Gdf5 mutation case report and a systematic review of molecular and clinical spectrum: expanding current knowledge on genotype-phenotype correlations. Bone, 144:115803, March 2021. URL: http://dx.doi.org/10.1016/j.bone.2020.115803, doi:10.1016/j.bone.2020.115803. This article has 9 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bone.2020.115803)